SPIRIT Small Vessel Registry

Abbott Medical Devices150 enrolled

Overview

To evaluate the safety and effectiveness of the 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in improving coronary luminal diameter in subjects with ischemic heart disease due to a maximum of two de novo native coronary artery lesions in small vessels, each in a different epicardial vessel.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

150

Conditions

Coronary Artery Disease Atherosclerosis Myocardial Ischemia

Interventions

2.25 mm XIENCE V® Everolimus Eluting Coronary Stent SystemDEVICE

Treatment of a maximum of two de novo native coronary artery lesions in small vessels.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

General Inclusion Criteria 1. Subject must be at least 18 years of age. 2. Subject or a legally authorized representative must provide written informed consent prior to any study related procedure. 3. Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or a reversible change in the electrocardiogram (ECG) consistent with ischemia). 4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery. 5. Subject must agree not to participate in any other clinical study for a period of one year following the index procedure. Angiographic Inclusion Criteria 1. One target or two (two target or one target and one non-target) de novo lesion(s), each in a different epicardial vessel. 2. If there are two target lesions or one target and one non-target lesion, both lesions must satisfy the angiographic eligibility criteria. 3. The target lesion(s) or non-target lesion must be located in a major artery or branch with a visually estimated diameter stenosis of ≥50% and \< 100% with a TIMI flow of ≥1. 4. The target lesion(s) or non-target lesion must be located in a native coronary artery with a reference vessel diameter by visual estimation of: Target Lesion: ≥ 2.25 mm to \< 2.5 mm for treatment by the 2.25 mm XIENCE V® EECS. Non-target Lesion: ≥2.5 mm to ≤4.25 mm for treatment by the commercial XIENCE V® EECS. 5. The target lesion(s) or non-target lesion must be located in a native coronary artery with a lesion length by visual estimation of ≤28 mm. General Exclusion Criteria 1. Subject has had a known diagnosis of acute myocardial infarction (AMI) preceding the index procedure (CK-MB (creatine kinase myocardial-band isoenzyme) ≥2 times the upper limit of normal) and CK and CK-MB levels have not returned to within normal limits at the time of procedure. 2. The subject is currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes. 3. Subject has current unstable cardiac arrhythmias associated with hemodynamic instability. 4. Subject has a known left ventricular ejection fraction (LVEF) \< 30% (LVEF may be obtained at the time of the index procedure if the value is unknown and if necessary). 5. Subject has received coronary brachytherapy in any epicardial vessel. 6. Subject has received any organ transplant or is on a waiting list for any organ transplant. 7. Subject is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or within one year after the index procedure. 8. Subject is receiving or scheduled to receive planned radiation therapy to the chest or mediastinum. 9. Subject is receiving immunosuppressant therapy or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.). 10. Subject is receiving chronic anticoagulation therapy (e.g., heparin, coumadin). 11. Subjects who will require Low Molecular Weight Heparin (LMWH) post-procedure. 12. Subject has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, everolimus, cobalt, chromium, nickel, tungsten, acrylic and fluoropolymers or contrast sensitivity that cannot be adequately pre-medicated. 13. Elective surgery is planned within 12 months after the procedure that will require discontinuing either aspirin or clopidogrel. 14. Subject has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3, a WBC (white blood cell) of \< 3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis). 15. Subject has known renal insufficiency (eg, serum creatinine level ≥ 2.5 mg/dL, or on dialysis). 16. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions. 17. Subject has had a cerebrovascular accident/stroke or transient ischemic neurological attack (TIA) within the past six months. 18. Subject has had a significant gastro-intestinal or significant urinary bleed within the past six months. 19. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath insertion. 20. Subject has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year). 21. Subject is currently participating in another clinical study that has not yet completed its primary endpoint. 22. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test. Angiographic Exclusion Criteria 1. Target lesion(s) or non-target lesion located within an arterial or saphenous vein graft or distal to a diseased (vessel irregularity per angiogram and \> 20% stenosed lesion by visual estimation) arterial or saphenous vein graft. 2. Target lesion(s) or non-target lesion involving a bifurcation with a side branch ≥2 mm in diameter and/or ostial lesion \> 40% stenosed by visual estimation or side branch requiring protection guide wire, or side branch requiring dilatation. 3. Total occlusion (TIMI flow 0), prior to crossing with the wire. 4. Another lesion requiring revascularization is located in the same epicardial vessel of either the target or non-target lesion. 5. Restenotic lesion. 6. Aorto-ostial lesion (within 3 mm of the aorta junction). 7. Left main location. 8. Lesion located within 2 mm of the origin of the LAD (left anterior descending) or LCX (left coronary artery) 9. Extreme angulation (≥90°) or excessive tortuosity (≥ two 45° angles) proximal to or within the target or non-target lesion. 10. Heavy calcification proximal to or within the target or non-target lesion(s). 11. Target or non-target vessel contains thrombus as indicated in the angiographic images. 12. Target lesion(s) or non-target lesion have a high probability that a procedure other than pre-dilatation and stenting will be required at the time of index procedure for treating the target and non-target vessel(s) (e.g. atherectomy, cutting balloon). 13. Target or non-target vessel(s) have previously been treated with percutaneous intervention (e.g. balloon angioplasty, stent, cutting balloon, atherectomy) \< 9 months prior to index procedure. 14. A vessel not intended to be treated with a 2.25 mm XIENCE V® EECS or commercial sizes of XIENCE V® EECS that was previously treated with any type of PCI (percutaneous coronary intervention) \< 90 days prior to the index procedure. 15. Additional clinically significant lesion(s) (e.g., %DS (diameter stenosis) ≥ 50%) is present in any vessel or side branch for which PCI may be required \< 90 days after the index procedure.

Locations (34)

Outcomes

Primary Outcomes

Composite Rate of Cardiac Death, Target Vessel Myocardial Infarction (MI) (Per Protocol Definition) & Clinically Indicated Target Lesion Revascularization (CI-TLR).

This endpoint is a composite of cardiac death, target vessel myocardial infarction per protocol definition, and clinically-indicated target lesion revascularization.

Time frame: 1 year

Composite Rate of Cardiac Death, Target Vessel Myocardial Infarction (MI) (Per Protocol Definition) & Clinically Indicated Target Lesion Revascularization (CI-TLR).

This endpoint is a composite of cardiac death, target vessel myocardial infarction per protocol definition, and clinically-indicated target lesion revascularization.

Time frame: 2 years

Composite Rate of Cardiac Death, Target Vessel Myocardial Infarction (MI) (Per Protocol Definition) & Clinically Indicated Target Lesion Revascularization (CI-TLR).

This endpoint is a composite of cardiac death, target vessel myocardial infarction per protocol definition, and clinically-indicated target lesion revascularization.

Time frame: 3 years

Secondary Outcomes

Device Success (Per Lesion Basis, for Target Lesions Treated by 2.25 mm XIENCE V EECS With or Without Planned Overlap)

Successful delivery and deployment of the first study stent intended to be implanted at the intended target lesion (or intended first and second investigational stents for overlapping stents), successful withdrawal of the stent delivery system, and attainment of final residual stenosis of \<50%.

Time frame: From start of index procedure to end of index procedure

Procedural Success (Per Subject Basis, for ALL Target and Non-target Lesions)

Achievement of a final in-stent diameter stenosis of \<50% using the study device, without the occurence of cardiac death, target vessel myocardial infarction per protocol definition, or repeat revascularization of the target lesion during the hospital stay up to 7 days.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Scottsdale Healthcare

Scottsdale, Arizona, United States

Arkansas Heart Hospital

Little Rock, Arkansas, United States

Washington Hospital Center

Washington D.C., District of Columbia, United States

Morton Plant Hospital

Clearwater, Florida, United States

Sacred Heart Hospital

Pensacola, Florida, United States

St. Anthony Hospital

Rockford, Illinois, United States

St. John's Hospital / Prairie Education & Research Cooperative

Springfield, Illinois, United States

Union Memorial Hospital

Baltimore, Maryland, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

St. Joseph Medical Center

Towson, Maryland, United States

...and 24 more locations

Time frame: From the start of index procedure to end of index procedure

In-Stent Late Loss

In-stent minimum lumen diameter (MLD) post-procedure minus in-stent MLD at angiographic follow-up.

Time frame: 240 days

In-segment Late Loss (LL)

In-segment minimum lumen diameter (MLD) post-procedure minus in-segment MLD at angiographic follow-up.

Time frame: 240 Days

Proximal Late Loss

Proximal minimum lumen diameter (MLD) post-procedure minus proximal MLD at angiographic follow-up (proximal defined as 5 mm of healthy tissue proximal to stent placement).

Time frame: 240 days

Distal Late Loss

Distal minimum lumen diameter (MLD) post-procedure minus distal MLD at angiographic follow-up (distal defined as 5 mm of healthy tissue distal to stent placement).

Time frame: 240 days

In-stent % Diameter Stenosis

Value calculated as 100\*(1-MLD/RVD) where MLD is in-stent minimum lumen diameter and RVD is in-stent reference vessel diameter.

Time frame: 240 days

In-segment % Diameter Stenosis

Value calculated as 100\*(1-MLD/RVD) where MLD is in-segment minimum lumen diameter and RVD is in-segment reference vessel diameter.

Time frame: 240 days

Proximal % Diameter Stenosis

Value calculated as 100\*(1-MLD/RVD) where MLD is minimum lumen diameter and RVD is reference vessel diameter in 5 mm of healthy tissue proximal to stent placement.

Time frame: 240 days

Distal % Diameter Stenosis

Value calculated as 100\*(1-MLD/RVD) where MLD is minimum lumen diameter and RVD is reference vessel diameter in 5 mm of healthy tissue distal to stent placement.

Time frame: 240 days

In-stent Angiographic Binary Restenosis (ABR) Rate

Percentage of patients with target lesions with ≥ 50% in-stent % diameter stenosis at angiographic follow-up.

Time frame: 240 days

In-segment Angiographic Binary Restenosis (ABR) Rate

Percentage of patients with target lesions with ≥ 50% in-segment % diameter stenosis at angiographic follow-up.

Time frame: 240 days

Proximal Angiographic Binary Restenosis (ABR) Rate

Percentage of patients with target lesions with ≥ 50% diameter stenosis in 5 mm of healthy tissue proximal to stent placement at angiographic follow-up.

Time frame: 240 days

Distal Angiographic Binary Restenosis (ABR) Rate

Percentage of patients with target lesions with ≥ 50% diameter stenosis in 5 mm of healthy tissue distal to stent placement at angiographic follow-up.

Time frame: 240 days

All Death (Cardiac, Vascular, Non-cardiovascular)

All death, including death from cardiac, vascular, and non-cardiovascular causes.

Time frame: 30 days

All Death (Cardiac, Vascular, Non-cardiovascular)

All death, including death from cardiac, vascular, and non-cardiovascular causes.

Time frame: 240 days

All Death (Cardiac, Vascular, Non-cardiovascular)

All death, including death from cardiac, vascular, and non-cardiovascular causes.

Time frame: 1 year

All Death (Cardiac, Vascular, Non-cardiovascular)

All death, including death from cardiac, vascular, and non-cardiovascular causes.

Time frame: 2 years

All Death (Cardiac, Vascular, Non-cardiovascular)

All death, including death from cardiac, vascular, and non-cardiovascular causes (per protocol).

Time frame: 3 years

Target Vessel MI - Q-wave and Non Q-wave (Per Protocol)

Target vessel myocardial infarction (MI) (MI not clearly attributable to a non-target vessel), including Q-wave MI (new pathologic Q waves) and Non Q-wave MI (elevation of CK to ≥ two times the upper limit normal with elevated CK-MB in the absence of new pathological Q waves).

Time frame: 30 days

Target Vessel MI - Q-wave and Non Q-wave (Per Protocol)

Time frame: 240 days

Target Vessel MI - Q-wave and Non Q-wave (Per Protocol)

Time frame: 1 year

Target Vessel MI - Q-wave and Non Q-wave (Per Protocol)

Time frame: 2 years

Target Vessel MI - Q-wave and Non Q-wave (Per Protocol)

Time frame: 3 years